Hernández-Chiñas Ulises, Chávez-Berrocal María E, Ahumada-Cota Ricardo E, Navarro-Ocaña Armando, Rocha-Ramírez Luz M, Pérez-Del Mazo Yolanda, Alvarado-Cabello Maribel, Pérez-Soto Gabriel, León-Alamilla Luis A, Acevedo-Monroy Salvador E, Esquiliano Diego, Raya-Rivera Atlántida M, Eslava Carlos A
Peripheral Unit of Basic and Clinical Research in Infectious Diseases, Public Health Department, Research Division, Faculty of Medicine Universidad Nacional Autónoma de México, Bacterial Pathogenicity Laboratory, Hemato-Oncology and Research Unit, Children's Hospital of Mexico Federico Gómez, Dr. Márquez 162, Col. De los Doctores, Mexico City 06720, Mexico.
Bacteriology Laboratory, Public Health Department, Faculty of Medicine, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Ciudad Universitaria, Mexico City 04510, Mexico.
Microorganisms. 2021 Aug 26;9(9):1811. doi: 10.3390/microorganisms9091811.
Antimicrobial bacteria resistance is an important problem in children with recurrent urinary tract infections (rUTI), thus it is crucial to search for alternative therapies. Autologous bacterial lysates (ABL) may be a potential treatment for rUTI. Twenty-seven children with rUTI were evaluated for one year, urine and stool cultures were performed, 10 colonies of each culture were selected and those identified as were characterized by serology. For patients who presented ≥10 UFC/mL, an ABL was manufactured and administered orally (1 mL/day) for a month. Twelve children were monitored for ≥1-year, 218 urine and 11 stool samples were analyzed. (80.5%) was the main bacteria isolated from urine and feces (72%). of classical urinary serotypes (UPEC), O25:H4, O75:HNM, and O9:HNM were identified in patients with persistent urinary infection (pUTI). In 54% of patients treated with ABL, the absence of bacteria was observed in urine samples after 3 months of treatment, 42% of these remained without UTI between 10-12 months. It was observed that the use of ABL controlled the infection for almost 1 year in more than 60% of the children. We consider it necessary to develop a polyvalent immunogen for the treatment and control of rUTI.
抗菌药物耐药性是复发性尿路感染(rUTI)患儿面临的一个重要问题,因此寻找替代疗法至关重要。自体细菌裂解物(ABL)可能是rUTI的一种潜在治疗方法。对27例rUTI患儿进行了为期一年的评估,进行了尿液和粪便培养,从每种培养物中选取10个菌落,并对那些鉴定为[此处原文缺失具体鉴定内容]的菌落进行血清学特征分析。对于尿细菌计数≥10 UFC/mL的患者,制备ABL并口服给药(1 mL/天),持续一个月。对12名患儿进行了≥1年的监测,分析了218份尿液和11份粪便样本。[此处原文缺失具体细菌名称](80.5%)是从尿液和粪便中分离出的主要细菌(72%)。在持续性尿路感染(pUTI)患者中鉴定出了经典尿路血清型(UPEC)的[此处原文缺失具体血清型内容],即O25:H4、O75:HNM和O9:HNM。在接受ABL治疗的患者中,54%在治疗3个月后尿液样本中未检测到细菌,其中42%在10 - 12个月期间未发生UTI。观察到使用ABL可使超过60%的患儿的感染得到近1年的控制。我们认为有必要开发一种多价免疫原用于rUTI的治疗和控制。